Following a complete dismissal of a heavily contested ERISA class action against client American Century Companies, Jamie Fleckner is featured in a Law360 Q&A about what the ruling means for the industry, his practice and issues affecting ERISA litigation.
Read the full Q&A.
Related Content
- AlertApril 9, 2024
The Department of Labor Finalizes Changes to the QPAM Exemption – A Favored Management Tool Gets Less User-Friendly
- AlertJanuary 10, 2024
Deadline Approaching for Reporting 2023 ISO Exercises and ESPP Transfers
- AlertDecember 29, 2023
Rushing to Chaos: The U.S. Department of Labor’s Well-Intentioned, Yet Unworkable Proposal to Redefine Fiduciary Investment Advice
- InsightJuly 19, 2023
ERISA Litigation Update
- AlertApril 19, 2023
A Step Towards Guidance Instead of Regulation by Litigation in the ESOP Space
- InsightApril 11, 2023
ERISA Litigation Update
- AlertMarch 3, 2023
Part III: What Primary Mitigation Strategies Exist for Companies with Double-Vest RSUs That May Be Expiring?
- AlertFebruary 23, 2023
Part II: Why Do Private Companies Shift From Stock Options to Double-Vest RSUs?
- Press ReleaseApril 16, 2024
Goodwin Represents the Underwriters in PACS Group $450 Million IPO
- In the PressApril 12, 2024
Rash Of 401(k) Forfeiture Suits Approach First Hurdles (Law360)
- Press ReleaseMarch 25, 2024
FASHIONPHILE Acquires Two Authenticators Inc. Business
- Press ReleaseMarch 22, 2024
Astera Labs Completes Upsized $774 Million Initial Public Offering
- Press ReleaseMarch 19, 2024
Fusion Pharmaceuticals To Be Acquired By AstraZeneca
- In the PressJanuary 26, 2024
John Hancock Gets Warm Reception in Foreign Tax Credit Appeal (Bloomberg Law)
- In the PressJanuary 26, 2024
John Hancock Clients Owed Tax Credit Perk, 11th Circ. Told (Law360)
- Press ReleaseJanuary 16, 2024
Myrobalan Therapeutics Completes Series A Financing of $24 Million to Develop Potentially First-in-Class CNS Therapeutics with Restorative Potential